TAA06-UCAR-gammadeltaT is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TAA06-UCAR-gammadeltaT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TAA06-UCAR-gammadeltaT overview
TAA06-UCAR-gammadeltaT is under development for the treatment of advanced solid tumors including ovarian cancer and relapsed and refractory acute myeloid leukemia. The therapeutic candidate comprises of allogenic gamma delta T cells genetically engineered to express chimeric antigen receptors (UCAR-T). It is administered through parenteral route.
PersonGen BioTherapeutics (Suzhou) overview
PersonGen BioTherapeutics (Suzhou) (PersonGen) is a biotechnology company focused on developing CAR-related therapies, analytical antibodies, novel CAR-T therapeutics, and allogeneic cellular therapies. PersonGen is headquartered in Suzhou, Jiangsu, China.
For a complete picture of TAA06-UCAR-gammadeltaT’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
